Fluvastatin conjugated with human immunodeficiency virus type 1 (HIV-1) trans-activator transcription peptide (TAT) produces anti-proliferative action against human hepatoma cancer cells through a concomitant accumulation of cells in the pre-G phase and induction of caspase 3 cleavage [82]. The gene discussed is CASP3; the disease is cancer.